Online inquiry

IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1617MR)

This product GTTS-WQ1617MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets GDF11 gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005811.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10220
UniProt ID O95390
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1617MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12969MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PDL 192
GTTS-WQ12228MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ7320MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FPA-144
GTTS-WQ11343MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ569MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 62-71-3
GTTS-WQ4058MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI 655130
GTTS-WQ12017MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MM-302
GTTS-WQ8412MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HSP90mab
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW